

EN
E-002921/2024
Answer given by Ms Lahbib
on behalf of the European Commission
(10.3.2025)

Under the EU vaccines strategy¹, the Commission concluded on behalf of Member States an Advance Purchase Agreement (APA)² with CureVac in November 2020 in order to secure up to 405 million doses of their *CVnCoV* vaccine and made an upfront payment to the company in December 2020 as per the contractual provisions.

In October 2021, CureVac notified the Commission of its inability to start the provision of the vaccine. In accordance with the contract provisions, CureVac presented to the Commission a Financial Statement of the total expenses incurred and commitments made for the *CVnCoV* project costs and investments. The Commission is in the process of assessing the company's declaration to verify the correctness and eligibility of the expenditures in the Financial Statement (including the EUR 19.6 million of commitments referenced in the European Court of Auditors (ECA) report) against the provisions of the APA.

After the mentioned upfront payment to CureVac, the Commission did not make further payments to CureVac nor to other manufacturers of COVID-19 vaccines in 2023. The Financial Statement of CureVac was subject to the ECA Report 2023 because the period under examination by the Court of Auditors in the Annual Report 2023³ also covers retroactively periods before 2023, as explained in footnote 10 on page 25 of the report.

¹ https://commission.europa.eu/strategy-and-policy/coronavirus-response/public-health/eu-vaccines-strategy_en

² https://commission.europa.eu/system/files/2021-01/curevac_-_redacted_advance_purchase_agreement_0.pdf

³ https://www.eca.europa.eu/ECAPublications/AR-2023/AR-2023_EN.pdf